Immunotherapy in Bladder Cancer: FDA Updates Labels, Approves Diagnostic Tools

Article

The Food and Drug Administration (FDA) updated the prescribing information for two immunotherapy agents – Keytruda (pembrolizumab) and Tecentriq (atezolizumab) – approved to treat patients with locally advanced or metastatic bladder cancer who are not eligible for cisplatin-based therapy.

The Food and Drug Administration (FDA) updated the prescribing information for two immunotherapy agents — Keytruda (pembrolizumab) and Tecentriq (atezolizumab) – approved to treat patients with locally advanced or metastatic bladder cancer who are not eligible for cisplatin-based therapy.

Physicians must now use an FDA-approved companion diagnostic tool to test PD-L1 levels in patients’ tumor tissue before prescribing Keytruda or Tecentriq, the agency said. Two such tools were granted FDA approval this summer: the Dako PD-L1 IHC 22C3 PharmDx Assay and the Ventana PD-L1 (SP142) Assay.

PD-L1 is a protein that interacts with another protein, PD-1, and together they tell a person’s immune system not to attack cancer cells. Keytruda and Tecentriq both inhibit PD-L1’s activity, signaling to the immune system that cancer cells are something foreign and dangerous that the immune system should attack.

The Dako PD-L1 IHC 22C3 PharmDx Assay was approved as a diagnostic tool that will select patients with locally advanced or metastatic bladder cancer who are cisplatin-ineligible for treatment with Keytruda. Now using this tool, this group of patients will be deemed eligible for Keytruda if they have a combined positive score (CPS) PD-L1 status of 10 or higher. The drug is also approved for patients with bladder cancer who are not eligible for platinum-containing chemotherapy, regardless of PD-L1 status.

To be prescribed Tecentriq, cisplatin-ineligible patients with advanced or metastatic disease must undergo the Ventana PD-L1 (SP142) Assay, which determines PD-L1 expression on immune cells.

Now, Tecentriq is indicated to treat patients with locally advanced or metastatic bladder cancer who are not eligible for cisplatin-containing chemo and whose tumors express a 5 percent or higher PD-L1 staining, as determined by the new test or for patients who are not eligible for any platinum-containing therapy, regardless of their PD-L1 status.

Back in June, the FDA updated the labels for Keytruda and Tecentriq for existing frontline approvals for platinum-ineligible patients with bladder cancer.

Related Videos
Woman with dark brown hair and pink lipstick wearing a light pink blouse with a light brown blazer. Patients should have conversations with their providers about treatments after receiving diagnoses.
Dr. Psutka in an interview with CURE
Dr. Sarah Psutka in an interview with CURE at the ASCO Annual Meeting
Kristie L. Kahl and Dr. Tracy L. Rose
Dr. Tracy Rose
Dr. Tracy L. Rose
Kristie L. Kahl and Tracy L. Rose
Kristie L. Kahl
Related Content